Zimmer Biomet Holdings Inc. has named Jonathan M. Vigdorchik, M.D., as chief science, technology and medical affairs officer, effective April 14.

In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of Zimmer Biomet’s global end-to-end technology portfolio, including artificial intelligence (AI), robotics, smart implants, and data. He will also oversee Zimmer Biomet’s Medical Education strategy and Global Advisory Board, helping further strengthen the company’s clinical engagement, innovation roadmap, and external scientific leadership. Dr. Vigdorchik will report to Chairman/President/CEO Ivan Tornos.

“Dr. Vigdorchik is a world-class orthopedic surgeon, and he brings exactly the kind of bold, future-focused leadership we need as we continue to shape the next era of musculoskeletal care,” Tornos said. “He understands how to translate clinical insight into meaningful innovation, and his leadership will help us move faster, think bigger, and continue advancing our broad suite of robotic and enabling technologies. I’m confident he will play a critical role in accelerating our portfolio strategy and further differentiating Zimmer Biomet in the market.”

Dr. Vigdorchik was Zimmer Biomet’s chief medical technology advisor for adult reconstruction and hip implants. He is a board-certified, fellowship-trained orthopedic surgeon at Hospital for Special Surgery (HSS) in New York City, specializing in hip and knee replacement surgery. Dr. Vigdorchik has held several academic and clinical leadership positions, including serving as division chief for national/international reputation and academic promotion on the Adult Reconstruction and Joint Replacement service at HSS and director of Bone Implant Longevity Research at HSS’s Griffin Research Accelerator. In addition, he is currently an associate professor of Orthopaedic Surgery at Weill Cornell Medical College. He is active in professional societies, including The Hip Society, The Knee Society, the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS), where he served as the Education and Communications Council chair and earlier served as program chair for the 2024 AAHKS Annual Meeting.

“As a surgeon and innovator, I believe we are at an inflection point where AI, data, and advanced technology will fundamentally redefine the future of orthopedics,” Dr. Vigdorchik stated. “I’ve dedicated my career to focus on preventing complications and achieving consistently better outcomes for patients. With strength across its product portfolio, a differentiated suite of robotic and enabling technologies, and a pathway toward fully autonomous robotic technology in orthopedics, Zimmer Biomet is poised to continue pushing the industry forward. I’m excited to join the team in this expanded role to help advance that vision and accelerate innovation for surgeons and patients around the world.”

Dr. Vigdorchik earned his medical degree from the University of Missouri – Columbia School of Medicine, completed his orthopedic surgery residency at the Detroit Medical Center/Providence Hospital, and received fellowship training in adult reconstruction and joint replacement at HSS. He also completed an international traveling fellowship in hip preservation surgery with training at centers in Switzerland, Boston Children’s Hospital, and Washington University in St. Louis.

Zimmer Biomet is a global medical technology company with a portfolio designed to maximize mobility and improve health. Its products and integrated digital and robotic solutions leverage data, data analytics, and artificial intelligence. Leveraging more than 90 years of leadership and expertise, Zimmer Biomet maintains operations in over 25 countries and sells its products in 100-plus countries.